Navigation Links
ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
Date:2/25/2009

HALIFAX, NS, Feb. 25 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has signed a collaborative agreement with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in Maryland, USA. The research collaboration involves formulating NIAID antigens in DepoVax(TM), IVT's vaccine enhancement system, and exploring potential vaccines for HIV and malaria.

"NIAID is a world leader in the study of infectious and immune-mediated disease, and we look forward to seeing how our enhanced DepoVax(TM) delivery system augments this research," said Dr. Marc Mansour, vice president of R&D at IVT.

There are currently a limited number of vaccine formulations capable of inducing potent and durable T cell responses. Several vaccines in development, based on replication-defective adenovirus, are limited in their ability to be used repeatedly. There is an urgent need to develop protein vaccines that can induce antibody and T cell responses, and be used in combination with other vaccines. The goal of this pre-clinical research collaboration is to establish whether a novel vaccine formulation, in which a specified protein is formulated in DepoVax(TM), will induce stronger T cell responses compared to other protein-based formulations. Proteins from HIV, SIV and malaria will be tested.

ABOUT IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a privately held, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

www.immunovaccine.com.

ABOUT NIAID and NIH

NIAID conducts and supports research-on the NIH campus, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. www.niaid.nih.gov. The National Institutes of Health (NIH)-The Nation's Medical Research Agency-includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. www.nih.gov.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
2. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
3. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
4. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
5. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
6. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
7. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
8. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, announces launch of its new Surge(TM) ... Dave Johnson, PhD, CEO of GigaGen, will present on Surge at the conference. ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has ... years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies ... team is Kati Abraham , who is well known in the industry and ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... solutions, today announced that its Anzo Smart Data Lake® (Anzo SDL) solution ... category for the 2017 Software & Information Industry Association (SIIA) CODiE Awards. ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, ... B round of financing in the amount of $6 million. An investment vehicle ... in the round. , The Series B funding will enable Cybrexa to complete ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):